Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mortality

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,336 result(s) found for: Mortality. Displaying page 59 of 117.
    EudraCT Number: 2015-005256-97 Sponsor Protocol Number: SGI-110-06 Start Date*: 2017-06-19
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) ES (Completed) GB (Completed) FR (Completed) PL (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001429-30 Sponsor Protocol Number: WA42294 Start Date*: 2021-03-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) DE (Prematurely Ended) SE (Prematurely Ended) GR (Prematurely Ended) HU (Completed) PT (Prematurely Ended) AT (Prematurely Ended) FI (Completed) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001489-17 Sponsor Protocol Number: SIOPENRNET003 Start Date*: 2006-11-17
    Sponsor Name:St. Anna Kinderkrebsforschung e.V.
    Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
    Medical condition: High Risk Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) DK (Restarted) IT (Completed) IE (Completed) HU (Completed) FI (Completed) SI (Completed) PL (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001700-21 Sponsor Protocol Number: 20130320 Start Date*: 2015-02-19
    Sponsor Name:Amgen Inc.
    Full Title: An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia...
    Medical condition: Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    20.0 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021591-28 Sponsor Protocol Number: TMC-CAN-10-01 Start Date*: 2011-01-05
    Sponsor Name:The Medicines Company
    Full Title: A clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention
    Medical condition: Subjects with coronary atheroschlerosis who require PCI
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) IT (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-002253-30 Sponsor Protocol Number: INCB39110-120 Start Date*: 2019-07-01
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in...
    Medical condition: Male or female, 28 days to less than 18 years of age, who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001360-19 Sponsor Protocol Number: ADN011 Start Date*: 2016-01-04
    Sponsor Name:ADIENNE SA
    Full Title: Prospective, phase II/III, randomized clinical study to compare BEGEDINA® versus “conventional treatment” for treating steroid resistant acute graft-versus host disease
    Medical condition: steroid resistant acute graft versus host disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002220-16 Sponsor Protocol Number: D4194C00006 Start Date*: 2019-02-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung C...
    Medical condition: Patients with unresectable Stage III non-small cell lung cancer (NSCLC), who have not progressed following platinum-based sequential chemoradiation therapy (sCRT)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004915-30 Sponsor Protocol Number: HO113 Start Date*: 2013-09-05
    Sponsor Name:HOVON Foundation
    Full Title: Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III, randomized double-blind multi-center HOVON study.
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    19.1 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001789-28 Sponsor Protocol Number: IG1601 Start Date*: 2018-04-25
    Sponsor Name:Instituto Grifols S.A.
    Full Title: Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites
    Medical condition: Subjects with decompensated cirrhosis and ascites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10064704 Decompensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003561-16 Sponsor Protocol Number: TAK-242/01-04-TL-242-011 Start Date*: 2005-12-21
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis
    Medical condition: Severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8 10040047 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005468-10 Sponsor Protocol Number: C16011 Start Date*: 2012-11-28
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refra...
    Medical condition: Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (Prematurely Ended) IT (Completed) GR (Completed) ES (Prematurely Ended) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022395-31 Sponsor Protocol Number: AC-004-EU Start Date*: 2010-10-07
    Sponsor Name:E.M.N. - EUROPEAN MYELOMA NETWORK
    Full Title: A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL...
    Medical condition: AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035227 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Ongoing) DK (Completed) GB (GB - no longer in EU/EEA) GR (Ongoing) ES (Ongoing) DE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001336-62 Sponsor Protocol Number: 2019-ASPIREAF Start Date*: 2020-04-01
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial
    Medical condition: Perioperative atrial fibrillation after noncardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10042244 Stroke LLT
    20.0 100000004866 10005103 Bleeding LLT
    20.0 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-018141-20 Sponsor Protocol Number: IN0901INT Start Date*: 2010-06-30
    Sponsor Name:LEO Pharma A/S
    Full Title: Eficacia y Seguridad del Tratamiento a Largo Plazo (6 meses) con Innohep® frente a Anticoagulación con un Antagonista de la Vitamina K (Warfarina) para el Tratamiento del Tromboembolismo Venoso Agu...
    Medical condition: Tromboembolismo venoso (TEV) en pacientes con cáncer activo.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SK (Completed) CZ (Completed) AT (Completed) PT (Completed) IT (Completed) DK (Completed) GR (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-006719-20 Sponsor Protocol Number: 0431-082 Start Date*: 2009-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
    Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005278-59 Sponsor Protocol Number: 20050222 Start Date*: 2006-12-22
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symp...
    Medical condition: Heart Failure Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007559 Cardiac failure congestive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) LT (Completed) SK (Completed) BE (Completed) EE (Completed) FI (Completed) HU (Completed) DK (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) AT (Completed) PT (Completed) NL (Completed) LV (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005103-18 Sponsor Protocol Number: NC20971 Start Date*: 2008-03-21
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Synd...
    Medical condition: Stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019844-38 Sponsor Protocol Number: A6141116 Start Date*: 2010-08-12
    Sponsor Name:Pfizer, S.A
    Full Title: A double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of early the treatment with Eplerenone in patients with acute myocardial infarction. Estudio doble ciego, al...
    Medical condition: Infarto agudo de miocardio
    Disease: Version SOC Term Classification Code Term Level
    13 10000891 Infarto agudo de miocardio LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Completed) CZ (Completed) HU (Completed) GB (Completed) DE (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015713-51 Sponsor Protocol Number: 205.452 Start Date*: 2010-06-09
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG, Medical Affairs Germany
    Full Title: A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FI (Completed) LV (Completed) HU (Completed) NO (Completed) LT (Completed) SK (Completed) SE (Completed) ES (Completed) NL (Completed) DK (Completed) PT (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 12 14:37:14 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA